COVID‐19 Clinical Diagnostics and Testing Technology
Given the global nature of the coronavirus disease 2019 (COVID‐19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for...
Gespeichert in:
Veröffentlicht in: | Pharmacotherapy 2020-08, Vol.40 (8), p.857-868 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 868 |
---|---|
container_issue | 8 |
container_start_page | 857 |
container_title | Pharmacotherapy |
container_volume | 40 |
creator | Chau, Cindy H. Strope, Jonathan D. Figg, William D. |
description | Given the global nature of the coronavirus disease 2019 (COVID‐19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for detecting the novel coronavirus. We describe the current clinical diagnostics and technology, including molecular and serological testing approaches, for severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) testing as well as address their advantages and limitations. Nucleic acid amplification technology for molecular diagnostics remains the gold standard for virus detection. We highlight alternative molecular detection techniques used for developing novel COVID‐19 diagnostics on the horizon. Antibody response against SARS‐CoV‐2 remains poorly understood and proper validation of serology tests is necessary to demonstrate their accuracy and clinical utility. In order to bring the pandemic under control, we must speed up the development of rapid and widespread testing through improvements in clinical diagnostics and testing technology as well as access to these tools. |
doi_str_mv | 10.1002/phar.2439 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7361586</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2437267931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4439-8d8d483e42a00f11af0d3506f651d85f74b8e0155607a0c9cd0c48706ca4136b3</originalsourceid><addsrcrecordid>eNp1kctKAzEUhoMoWi8LX0AKbnQxenKZJLMRpF4qFCqibkOaybSRaVInVunOR_AZfRJTW0UFV-fA-fLxnxyEdjEcYQByPBnp5ogwWqygFpYizwqM2SpqAREiAwC5gTZjfEgo5oysow1KOKMEyxbinf791dn76xsu2p3aeWd03T5zeuhDfHImtrUv27c29X6Yqhn5UIfhbButVbqOdmdZt9Ddxfltp5v1-pdXndNeZliKk8lSlkxSy4gGqDDWFZQ0B17xHJcyrwQbSAs4zzkIDaYwJRgmBXCjGaZ8QLfQycI7mQ7GtjTWPzW6VpPGjXUzU0E79Xvi3UgNw7MSlONc8iQ4WAqa8DhNe6ixi8bWtfY2TKMijBAAWlCR0P0_6EOYNj6tlygqCBcFxYk6XFCmCTE2tvoOg0HNr6Hm15i_KBK79zP9N_n1_Qk4XgAvrraz_03qunt686n8AHM1kxc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2437267931</pqid></control><display><type>article</type><title>COVID‐19 Clinical Diagnostics and Testing Technology</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Chau, Cindy H. ; Strope, Jonathan D. ; Figg, William D.</creator><creatorcontrib>Chau, Cindy H. ; Strope, Jonathan D. ; Figg, William D.</creatorcontrib><description>Given the global nature of the coronavirus disease 2019 (COVID‐19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for detecting the novel coronavirus. We describe the current clinical diagnostics and technology, including molecular and serological testing approaches, for severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) testing as well as address their advantages and limitations. Nucleic acid amplification technology for molecular diagnostics remains the gold standard for virus detection. We highlight alternative molecular detection techniques used for developing novel COVID‐19 diagnostics on the horizon. Antibody response against SARS‐CoV‐2 remains poorly understood and proper validation of serology tests is necessary to demonstrate their accuracy and clinical utility. In order to bring the pandemic under control, we must speed up the development of rapid and widespread testing through improvements in clinical diagnostics and testing technology as well as access to these tools.</description><identifier>ISSN: 0277-0008</identifier><identifier>EISSN: 1875-9114</identifier><identifier>DOI: 10.1002/phar.2439</identifier><identifier>PMID: 32643218</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>antibody ; Antibody response ; antigen ; Betacoronavirus ; Clinical Laboratory Techniques ; Clinical Protocols ; Coronaviridae ; Coronavirus Infections - diagnosis ; Coronaviruses ; COVID-19 ; COVID-19 Testing ; Diagnostic Errors ; Humans ; Pandemics ; Pneumonia, Viral - diagnosis ; Point-of-Care Systems ; Real-Time Polymerase Chain Reaction ; Regular Manuscripts ; RT‐PCR ; SARS-CoV-2 ; Sensitivity and Specificity ; Serologic Tests - methods ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Special ; World Health Organization</subject><ispartof>Pharmacotherapy, 2020-08, Vol.40 (8), p.857-868</ispartof><rights>2020 Pharmacotherapy Publications, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4439-8d8d483e42a00f11af0d3506f651d85f74b8e0155607a0c9cd0c48706ca4136b3</citedby><cites>FETCH-LOGICAL-c4439-8d8d483e42a00f11af0d3506f651d85f74b8e0155607a0c9cd0c48706ca4136b3</cites><orcidid>0000-0003-2428-5613</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fphar.2439$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fphar.2439$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32643218$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chau, Cindy H.</creatorcontrib><creatorcontrib>Strope, Jonathan D.</creatorcontrib><creatorcontrib>Figg, William D.</creatorcontrib><title>COVID‐19 Clinical Diagnostics and Testing Technology</title><title>Pharmacotherapy</title><addtitle>Pharmacotherapy</addtitle><description>Given the global nature of the coronavirus disease 2019 (COVID‐19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for detecting the novel coronavirus. We describe the current clinical diagnostics and technology, including molecular and serological testing approaches, for severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) testing as well as address their advantages and limitations. Nucleic acid amplification technology for molecular diagnostics remains the gold standard for virus detection. We highlight alternative molecular detection techniques used for developing novel COVID‐19 diagnostics on the horizon. Antibody response against SARS‐CoV‐2 remains poorly understood and proper validation of serology tests is necessary to demonstrate their accuracy and clinical utility. In order to bring the pandemic under control, we must speed up the development of rapid and widespread testing through improvements in clinical diagnostics and testing technology as well as access to these tools.</description><subject>antibody</subject><subject>Antibody response</subject><subject>antigen</subject><subject>Betacoronavirus</subject><subject>Clinical Laboratory Techniques</subject><subject>Clinical Protocols</subject><subject>Coronaviridae</subject><subject>Coronavirus Infections - diagnosis</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 Testing</subject><subject>Diagnostic Errors</subject><subject>Humans</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - diagnosis</subject><subject>Point-of-Care Systems</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>Regular Manuscripts</subject><subject>RT‐PCR</subject><subject>SARS-CoV-2</subject><subject>Sensitivity and Specificity</subject><subject>Serologic Tests - methods</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Special</subject><subject>World Health Organization</subject><issn>0277-0008</issn><issn>1875-9114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctKAzEUhoMoWi8LX0AKbnQxenKZJLMRpF4qFCqibkOaybSRaVInVunOR_AZfRJTW0UFV-fA-fLxnxyEdjEcYQByPBnp5ogwWqygFpYizwqM2SpqAREiAwC5gTZjfEgo5oysow1KOKMEyxbinf791dn76xsu2p3aeWd03T5zeuhDfHImtrUv27c29X6Yqhn5UIfhbButVbqOdmdZt9Ddxfltp5v1-pdXndNeZliKk8lSlkxSy4gGqDDWFZQ0B17xHJcyrwQbSAs4zzkIDaYwJRgmBXCjGaZ8QLfQycI7mQ7GtjTWPzW6VpPGjXUzU0E79Xvi3UgNw7MSlONc8iQ4WAqa8DhNe6ixi8bWtfY2TKMijBAAWlCR0P0_6EOYNj6tlygqCBcFxYk6XFCmCTE2tvoOg0HNr6Hm15i_KBK79zP9N_n1_Qk4XgAvrraz_03qunt686n8AHM1kxc</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Chau, Cindy H.</creator><creator>Strope, Jonathan D.</creator><creator>Figg, William D.</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2428-5613</orcidid></search><sort><creationdate>202008</creationdate><title>COVID‐19 Clinical Diagnostics and Testing Technology</title><author>Chau, Cindy H. ; Strope, Jonathan D. ; Figg, William D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4439-8d8d483e42a00f11af0d3506f651d85f74b8e0155607a0c9cd0c48706ca4136b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>antibody</topic><topic>Antibody response</topic><topic>antigen</topic><topic>Betacoronavirus</topic><topic>Clinical Laboratory Techniques</topic><topic>Clinical Protocols</topic><topic>Coronaviridae</topic><topic>Coronavirus Infections - diagnosis</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 Testing</topic><topic>Diagnostic Errors</topic><topic>Humans</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - diagnosis</topic><topic>Point-of-Care Systems</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>Regular Manuscripts</topic><topic>RT‐PCR</topic><topic>SARS-CoV-2</topic><topic>Sensitivity and Specificity</topic><topic>Serologic Tests - methods</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Special</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chau, Cindy H.</creatorcontrib><creatorcontrib>Strope, Jonathan D.</creatorcontrib><creatorcontrib>Figg, William D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chau, Cindy H.</au><au>Strope, Jonathan D.</au><au>Figg, William D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID‐19 Clinical Diagnostics and Testing Technology</atitle><jtitle>Pharmacotherapy</jtitle><addtitle>Pharmacotherapy</addtitle><date>2020-08</date><risdate>2020</risdate><volume>40</volume><issue>8</issue><spage>857</spage><epage>868</epage><pages>857-868</pages><issn>0277-0008</issn><eissn>1875-9114</eissn><abstract>Given the global nature of the coronavirus disease 2019 (COVID‐19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for detecting the novel coronavirus. We describe the current clinical diagnostics and technology, including molecular and serological testing approaches, for severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) testing as well as address their advantages and limitations. Nucleic acid amplification technology for molecular diagnostics remains the gold standard for virus detection. We highlight alternative molecular detection techniques used for developing novel COVID‐19 diagnostics on the horizon. Antibody response against SARS‐CoV‐2 remains poorly understood and proper validation of serology tests is necessary to demonstrate their accuracy and clinical utility. In order to bring the pandemic under control, we must speed up the development of rapid and widespread testing through improvements in clinical diagnostics and testing technology as well as access to these tools.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32643218</pmid><doi>10.1002/phar.2439</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-2428-5613</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0277-0008 |
ispartof | Pharmacotherapy, 2020-08, Vol.40 (8), p.857-868 |
issn | 0277-0008 1875-9114 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7361586 |
source | MEDLINE; Wiley Online Library |
subjects | antibody Antibody response antigen Betacoronavirus Clinical Laboratory Techniques Clinical Protocols Coronaviridae Coronavirus Infections - diagnosis Coronaviruses COVID-19 COVID-19 Testing Diagnostic Errors Humans Pandemics Pneumonia, Viral - diagnosis Point-of-Care Systems Real-Time Polymerase Chain Reaction Regular Manuscripts RT‐PCR SARS-CoV-2 Sensitivity and Specificity Serologic Tests - methods Serology Severe acute respiratory syndrome coronavirus 2 Special World Health Organization |
title | COVID‐19 Clinical Diagnostics and Testing Technology |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T19%3A42%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID%E2%80%9019%20Clinical%20Diagnostics%20and%20Testing%20Technology&rft.jtitle=Pharmacotherapy&rft.au=Chau,%20Cindy%20H.&rft.date=2020-08&rft.volume=40&rft.issue=8&rft.spage=857&rft.epage=868&rft.pages=857-868&rft.issn=0277-0008&rft.eissn=1875-9114&rft_id=info:doi/10.1002/phar.2439&rft_dat=%3Cproquest_pubme%3E2437267931%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2437267931&rft_id=info:pmid/32643218&rfr_iscdi=true |